Form 4: Compass Therapeutics Director James P. Boylan Acquires Stock Options
SEC Form 4
Director James P. Boylan of Compass Therapeutics acquired stock options for 40,000 shares on March 8, 2024, vesting monthly starting April 8, 2024.
Summary
- On March 8, 2024, James P. Boylan, a director of Compass Therapeutics, Inc. (CMPX), acquired stock options for 40,000 shares.
- The exercise price of these options is $1.96 per share.
- The options vest over 48 substantially equal monthly installments, commencing on April 8, 2024.
- The options expire on March 7, 2034.
- Boylan is a member of Enavate Sciences, LP and holds the securities for their benefit, disclaiming beneficial ownership.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it is a standard disclosure of stock option grants to a director.
Industry Context
This Form 4 filing is a routine disclosure related to insider transactions and provides transparency to investors regarding the holdings and transactions of company insiders.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider activity.
- The vesting schedule aligns the director's interests with the long-term performance of the company.
Key Dates
| Date | Description |
|---|---|
| 03/08/2024 | Date of transaction: James P. Boylan acquired stock options. |
| 04/08/2024 | Vesting start date: Options vest over 48 months in substantially equal monthly installments. |
| 03/07/2034 | Expiration date: Stock options expire. |
| 03/11/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.